The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Future directions for HER2-mutant non-small cell lung cancer
Joshua Sabari, MD, New York University Langone Health, New York, NY, comments on the potential of combination strategies in HER2-mutant non-small cell lung cancer (NSCLC), including combinations with chemotherapy and antibody-drug conjugates (ADCs) like trastuzumab deruxtecan. However, clinicians need to closely monitor efficacy in context with toxicity profile and patient-reported outcomes to determine the benefits of these therapies. Additional brain-penetrant tyrosine kinase inhibitors under investigation include NVL-330, CGT4255, and IAM1363. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
